EDIT vs NTLA Stock Comparison: AI Score, Valuation, Performance and Upside
Editas Medicine and Intellia Therapeutics are both clinical-stage CRISPR gene editing companies, with Editas pursuing both ex vivo and in vivo editing approaches across its pipeline, while Intellia concentrates more specifically on in vivo gene editing approaches supported by strategic pharmaceutical partnerships.
Editas offers exposure to a diversified gene editing approach spanning both ex vivo and in vivo methods, while Intellia offers a more focused in vivo editing strategy backed by pharmaceutical partnerships. Consider whether you prefer Editas's diversified technical approach or Intellia's focused in vivo strategy with partnership validation.
EDIT holds the edge across 5 of 5 key metrics in this comparison. EDIT leads on both 1-year return (-10.00%) and forward P/E quality (-4.04x vs -4.90x for NTLA), a relatively favorable combination of momentum and valuation. EDIT leads on both revenue growth (232.30%) and operating margin (-167.31%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for EDIT (+97.04%) than for NTLA (+87.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Believe a diversified approach spanning both ex vivo and in vivo gene editing offers broader pipeline optionality
- Value the intellectual property position in foundational CRISPR technology
- Are comfortable with the substantial clinical and regulatory execution risk inherent in gene editing drug development
- Are willing to accept clinical-stage cash burn in exchange for multiple pipeline catalysts
- Believe in vivo gene editing approaches offer administration advantages over ex vivo editing methods
- Value strategic partnerships with larger pharmaceutical companies as validation and funding support
- See encouraging early clinical data in key indications as a positive sign for future pipeline success
- Are comfortable with the substantial clinical and regulatory execution risk inherent in gene editing drug development
| Metric | EDIT | NTLA |
|---|---|---|
| AI scorei | 26.9 | 24.5 |
| AI ranki | #2507 | #3227 |
| Latest closei | $2.70 | $12.14 |
| 1M returni | -16.92% | -8.58% |
| 6M returni | +15.38% | -5.45% |
| 1Y returni | -10.00% | -24.64% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EDIT | NTLA |
|---|---|---|
| 1Y ago | $9K (-10.0%) started 2025-09-18 | $7.54K (-24.6%) started 2025-09-18 |
| 5Y ago | $463.92 (-95.4%) started 2021-09-20 | $818.28 (-91.8%) started 2021-09-20 |
| 10Y ago | $1.83K (-81.7%) started 2016-09-19 | $6.37K (-36.3%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | EDIT | NTLA |
|---|---|---|
| Market capi | $467.65M | $1.79B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -4.04 | -4.90 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 5.86 | 23.75 |
| Analyst targeti | $6.00 | $23.94 |
| Target upsidei | +97.04% | +87.63% |
| Metric | EDIT | NTLA |
|---|---|---|
| Revenue growthi | 232.30% | -46.20% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | -94.28% | -419.83% |
| Operating margini | -167.31% | -1472.26% |
| Profit margini | -157.32% | 0.00% |
| ROIC proxyi | -118.82% | -55.44% |
| Return on equityi | -118.82% | -55.44% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 2.06 | 1.79 |
| Debt/equityi | 14.73 | 10.09 |
| Current ratioi | 3.19 | 6.65 |
| Quick ratioi | 3.13 | 5.61 |
Over the past year, EDIT and NTLA have moved moderately in the same direction (correlation of 0.60), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EDIT | NTLA |
|---|---|---|---|
| 1Y | Growthi | -10.00% | -24.64% |
| CAGRi | -10.01% | -24.66% | |
| Volatilityi | 83.69% | 94.51% | |
| Sharpe ratioi | 0.24 | 0.16 | |
| Sortino ratioi | 0.35 | 0.22 | |
| Max drawdowni | 59.88% | 71.27% | |
| Current drawdowni | 34.94% | 56.61% | |
| Avg drawdowni | 33.12% | 49.91% | |
| Ulcer Indexi | 36.13% | 52.95% | |
| Max daily dropi | 15.57% | 42.23% | |
| Max wkly dropi | 22.13% | 52.63% | |
| 5Y | Growthi | -95.36% | -91.82% |
| CAGRi | -45.93% | -39.42% | |
| Volatilityi | 93.43% | 77.97% | |
| Sharpe ratioi | -0.27 | -0.30 | |
| Sortino ratioi | -0.43 | -0.43 | |
| Max drawdowni | 98.42% | 95.96% | |
| Current drawdowni | 95.65% | 92.18% | |
| Avg drawdowni | 86.02% | 77.05% | |
| Ulcer Indexi | 87.19% | 79.53% | |
| Max daily dropi | 35.63% | 42.23% | |
| Max wkly dropi | 42.50% | 52.63% | |
| 10Y | Growthi | -81.69% | -36.31% |
| CAGRi | -15.62% | -4.41% | |
| Volatilityi | 84.10% | 78.49% | |
| Sharpe ratioi | 0.15 | 0.28 | |
| Sortino ratioi | 0.23 | 0.41 | |
| Max drawdowni | 98.92% | 96.45% | |
| Current drawdowni | 97.02% | 93.13% | |
| Avg drawdowni | 60.97% | 56.64% | |
| Ulcer Indexi | 69.03% | 63.89% | |
| Max daily dropi | 35.63% | 42.23% | |
| Max wkly dropi | 42.50% | 52.63% |
| Category | EDIT | NTLA |
|---|---|---|
| Company | Editas Medicine, Inc. | Intellia Therapeutics, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | A clinical-stage biotechnology company developing gene editing medicines using CRISPR technology, pursuing treatments for genetic diseases through both ex vivo and in vivo editing approaches. | A clinical-stage biotechnology company developing CRISPR-based gene editing therapies, with a focus on in vivo editing approaches that aim to edit genes directly inside the patient's body for genetic diseases. |
| Investor focus | Clinical trial progress across the gene editing pipeline, cash runway relative to development spending, and partnership or licensing agreement developments. | In vivo gene editing clinical trial progress, partnership and collaboration revenue, and cash runway relative to the pace of pipeline development spending. |
- CRISPR gene editing technology platform provides a differentiated approach to treating genetic diseases at their root cause
- Pipeline diversification across multiple gene editing programs offers several potential future clinical and regulatory catalysts
- Intellectual property position in foundational CRISPR technology provides potential licensing revenue opportunities
- Focus on in vivo gene editing approaches could offer simpler treatment administration compared to ex vivo editing methods
- Strategic partnerships with larger pharmaceutical companies provide funding support and validation of the technology platform
- Pipeline progress in genetic disease programs has generated encouraging early clinical data in key indications
- Clinical-stage status means the company has no significant approved product revenue, relying on cash reserves to fund operations
- Gene editing technology, while promising, still carries substantial clinical and regulatory execution risk across all pipeline programs
- Competitive gene editing landscape includes multiple well-funded companies pursuing similar therapeutic approaches
- Clinical-stage status means the company has no significant approved product revenue, relying on cash reserves and partnerships to fund operations
- In vivo gene editing technology, while differentiated, still carries substantial clinical and regulatory execution risk
- Competitive gene editing landscape includes multiple well-funded companies pursuing similar and alternative therapeutic approaches
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.